Gynostemma Tea (Gynostemma pentaphyllum)

Gynostemma pentaphyllum is an adaptogenic herb whose primary bioactive compounds, gypenosides, structurally resemble ginsenosides from panax ginseng and modulate AMPK pathways to support metabolic and anti-inflammatory functions. Preclinical research highlights its potential in blood sugar regulation, lipid metabolism, and oxidative stress reduction.

Origin & History

Gynostemma Tea derives from the leaves of Gynostemma pentaphyllum (Thunb.) Makino, a perennial climbing vine in the Cucurbitaceae family native to mountainous regions of China, Japan, and Korea. The tea is made from diploid and tetraploid cultivars, with tetraploid variants showing higher gypenoside yields (7.43 mg/g) in leaves.

Historical & Cultural Context

Known as 'Jiaogulan' in Traditional Chinese Medicine, Gynostemma pentaphyllum has been used for over 2,000 years as a tea for health maintenance, longevity, fatigue relief, and treating various ailments. It gained prominence in the 1980s as an adaptogen similar to ginseng, consumed as whole-leaf tea or decoctions throughout China, Japan, and Korea.

Health Benefits

• Anti-inflammatory effects: Gypenosides inhibited LPS-induced inflammation markers (IL-6, IL-1β, TNF-α, NO) in macrophage studies (preclinical evidence only)
• Potential anticancer activity: In vitro studies showed apoptosis and cell cycle arrest in colon, oral, and prostate cancer cell lines (no human data)
• Traditional longevity support: Used for over 2,000 years in TCM for health maintenance and longevity (traditional use only)
• Adaptogenic properties: Traditionally consumed as an adaptogen similar to ginseng (historical use, no clinical trials)
• Respiratory and digestive support: Traditional use for treating respiratory and digestive issues (no modern clinical evidence)

How It Works

Gypenosides activate AMP-activated protein kinase (AMPK), a key cellular energy sensor that enhances insulin sensitivity and suppresses hepatic glucose production via downregulation of PEPCK and G6Pase enzymes. Additionally, gypenosides inhibit NF-κB signaling, reducing transcription of pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α in macrophages. Some gypenosides also exhibit antioxidant activity by upregulating Nrf2/HO-1 pathways, reducing intracellular reactive oxygen species.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Gynostemma pentaphyllum or its tea/extracts. All available evidence is limited to preclinical in vitro studies using cell lines and traditional use documentation.

Clinical Summary

A small randomized controlled trial in patients with type 2 diabetes (n=24) found that gynostemma extract reduced fasting blood glucose and HbA1c over 12 weeks compared to placebo, though the sample size limits generalizability. A separate 4-week pilot study in overweight adults reported modest reductions in total cholesterol and LDL with standardized gynostemma extract at 450 mg/day. Anti-inflammatory and anticancer findings remain largely preclinical, derived from in vitro macrophage and cancer cell line studies with no confirmed human clinical equivalence. Overall, the evidence base is preliminary; larger, well-controlled human trials are needed before strong efficacy claims can be made.

Nutritional Profile

Gynostemma pentaphyllum leaf tea is a low-calorie beverage with negligible macronutrient content per typical serving (1–2g dried leaf per 200ml). Primary bioactive compounds are triterpenoid saponins called gypenosides (gynosaponins), with over 230 identified to date; dried leaf contains approximately 1–3% gypenosides by dry weight, with commercial extracts standardized to 20–98% gypenoside content. Notably, approximately 4 of these gypenosides are structurally identical or closely related to ginsenosides found in Panax ginseng (Rb1, Rd, F2, and Rg3 analogs). Polysaccharides are present at roughly 3–5% dry weight and contribute to immunomodulatory activity. Chlorophyll content is moderate (~1.5–2.5 mg/g dry leaf). Flavonoids including rutin, quercetin, and ombuoside are present at approximately 0.5–1.2% dry weight. Amino acid profile includes 18 amino acids with glutamic acid, aspartic acid, and glycine predominating; total free amino acid content estimated at 2–4% dry weight. Mineral content per 100g dry leaf includes potassium (~1,200–1,800 mg), calcium (~800–1,200 mg), magnesium (~200–350 mg), iron (~15–25 mg), zinc (~2–4 mg), and selenium (~0.05–0.15 mg). Vitamin content is modest: vitamin C (~40–80 mg/100g dry), beta-carotene precursor to vitamin A (~3–6 mg/100g dry), and small amounts of B vitamins including riboflavin and niacin. Bioavailability note: Gypenosides undergo significant first-pass intestinal microbial biotransformation; hydrolysis by gut microbiota releases aglycone forms (dammarane-type triterpenoids) which are more lipophilic and may exhibit enhanced cellular uptake, though systemic bioavailability data in humans is limited. Tea infusion captures water-soluble gypenosides, polysaccharides, flavonoids, and amino acids, but lipophilic compounds are poorly extracted without ethanol or other solvents.

Preparation & Dosage

No clinically studied dosages have been established in human trials. In vitro studies used gypenosides at 200 μg/ml, and commercial extracts vary from 1-10% gypenoside content by dry weight. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginseng, Rhodiola, Ashwagandha, Green Tea, Schisandra

Safety & Interactions

Gynostemma tea is generally considered safe when consumed as a traditional herbal tea, but high-dose standardized extracts may cause nausea, increased bowel movements, or mild dizziness in sensitive individuals. Due to its blood glucose-lowering activity via AMPK activation, concurrent use with antidiabetic medications such as metformin or insulin carries a risk of additive hypoglycemia requiring medical supervision. Gynostemma may also potentiate anticoagulant drugs like warfarin by inhibiting platelet aggregation, and individuals on blood thinners should consult a healthcare provider before use. Safety data during pregnancy and breastfeeding is insufficient, and use is not recommended in these populations.